Literature DB >> 17825626

A robust immunoassay for anti-interferon autoantibodies that is highly specific for patients with autoimmune polyglandular syndrome type 1.

Li Zhang1, Jennifer M Barker, Sunanda Babu, Maureen Su, Matthew Stenerson, Mickie Cheng, Anthony Shum, Ehud Zamir, Raffaele Badolato, Adam Law, George S Eisenbarth, Mark S Anderson.   

Abstract

UNLABELLED: High titer antibodies to type 1 interferons have been recently reported as being highly specific for patients with autoimmune polyglandular syndrome type 1 (APS1) in Finnish and Norwegian patients with mutations in the AIRE gene. Those studies employed a complex neutralization assay to define the type 1 interferon autoantibodies. Here we have established a competitive europium time resolved fluorescence assay for IFN-alpha autoantibodies and measured sera from subjects with APS1, first degree relatives of APS1 patients, patients with Addison's disease or Type 1 diabetes. The europium-based immunoassay utilizes plate bound human IFN-alpha incubated with sera with or without competition with fluid phase IFN-alpha, followed by anti-IgG biotinylated antibody and detection with streptavidin-europium. The index of IFN-alpha Ab was calculated as (CPS (Counts per second) without competition-CPS with competition)/(CPS positive standard sera without competition-CPS positive standard sera with competition). RESULTS are reported for raw CPS and indices and are compared across the different subjects.
RESULTS: For normal controls (n=100) CPS without competition were 31,237+/-17,328 CPS while after subtracting the competition value, the results were -6563+/-10,303 CPS. The initial APS1 patient (used to create the index as 1.0) gave 394,063 CPS without competition and a delta of 363,662+/-31,587 CPS with competition. Scatchard plot analysis of this patient sample revealed a high avidity for IFN-alpha (K(d) of 0.5 nM). The CPS, delta, and index for 6/7 APS1 patients were strongly positive and 3 standard deviations or more above that of the normal controls. Using a cut-off of 2 standard deviations above normal controls, relatives of APS1 patients were negative for type I interferon autoantibodies as were 71 patients with Addison's disease (non-APS1) and 141 Type 1 diabetes patients. This simple high throughput competitive europium time resolved fluorescence assay had a sensitivity of > or =86% or greater and a specificity of >99.5%.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17825626      PMCID: PMC2080870          DOI: 10.1016/j.clim.2007.07.015

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  19 in total

Review 1.  Autoimmune polyendocrinopathy syndrome type 1 (APS1) and AIRE gene: new views on molecular basis of autoimmunity.

Authors:  Pärt Peterson; Leena Peltonen
Journal:  J Autoimmun       Date:  2005-11-14       Impact factor: 7.094

Review 2.  Peripheral-antigen-expressing cells in thymic medulla: factors in self-tolerance and autoimmunity.

Authors:  D Hanahan
Journal:  Curr Opin Immunol       Date:  1998-12       Impact factor: 7.486

3.  Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy.

Authors:  Jaakko Perheentupa
Journal:  J Clin Endocrinol Metab       Date:  2006-05-09       Impact factor: 5.958

4.  Time-resolved immunofluorometry and other frequently used immunoassay types for follicle-stimulating hormone compared by using identical monoclonal antibodies.

Authors:  S Madersbacher; T Shu-Chen; S Schwarz; S Dirnhofer; G Wick; P Berger
Journal:  Clin Chem       Date:  1993-07       Impact factor: 8.327

5.  An autoimmune disease, APECED, caused by mutations in a novel gene featuring two PHD-type zinc-finger domains.

Authors: 
Journal:  Nat Genet       Date:  1997-12       Impact factor: 38.330

6.  Positional cloning of the APECED gene.

Authors:  K Nagamine; P Peterson; H S Scott; J Kudoh; S Minoshima; M Heino; K J Krohn; M D Lalioti; P E Mullis; S E Antonarakis; K Kawasaki; S Asakawa; F Ito; N Shimizu
Journal:  Nat Genet       Date:  1997-12       Impact factor: 38.330

Review 7.  Aire: an update.

Authors:  Maureen A Su; Mark S Anderson
Journal:  Curr Opin Immunol       Date:  2004-12       Impact factor: 7.486

8.  Common mutations in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy patients of different origins.

Authors:  H S Scott; M Heino; P Peterson; L Mittaz; M D Lalioti; C Betterle; A Cohen; M Seri; M Lerone; G Romeo; P Collin; M Salo; R Metcalfe; A Weetman; M P Papasavvas; C Rossier; K Nagamine; J Kudoh; N Shimizu; K J Krohn; S E Antonarakis
Journal:  Mol Endocrinol       Date:  1998-08

9.  Anti-interferon autoantibodies in autoimmune polyendocrinopathy syndrome type 1.

Authors:  Anthony Meager; Kumuthini Visvalingam; Pärt Peterson; Kaidi Möll; Astrid Murumägi; Kai Krohn; Petra Eskelin; Jaakko Perheentupa; Eystein Husebye; Yoshihisa Kadota; Nick Willcox
Journal:  PLoS Med       Date:  2006-07       Impact factor: 11.069

10.  Spontaneous autoimmunity prevented by thymic expression of a single self-antigen.

Authors:  Jason DeVoss; Yafei Hou; Kellsey Johannes; Wen Lu; Gregory I Liou; John Rinn; Howard Chang; Rachel R Caspi; Rachel Caspi; Lawrence Fong; Mark S Anderson
Journal:  J Exp Med       Date:  2006-11-20       Impact factor: 14.307

View more
  21 in total

Review 1.  The Immune Tolerance Network at 10 years: tolerance research at the bedside.

Authors:  Jeffrey A Bluestone; Hugh Auchincloss; Gerald T Nepom; Daniel Rotrosen; E William St Clair; Laurence A Turka
Journal:  Nat Rev Immunol       Date:  2010-11       Impact factor: 53.106

2.  The next big idea.

Authors:  Marian Rewers
Journal:  Diabetes Technol Ther       Date:  2013-06       Impact factor: 6.118

3.  MAS-1 adjuvant immunotherapy generates robust Th2 type and regulatory immune responses providing long-term protection from diabetes in late-stage pre-diabetic NOD mice.

Authors:  Li Zhang; Pilar Londono; Liping Yu; Stephen Grimes; Peter Blackburn; Peter Gottlieb; George S Eisenbarth
Journal:  Autoimmunity       Date:  2014-05-01       Impact factor: 2.815

Review 4.  Autoimmune polyendocrinopathy candidiasis ectodermal dystrophy.

Authors:  Kai Kisand; Pärt Peterson
Journal:  J Clin Immunol       Date:  2015-07-05       Impact factor: 8.317

Review 5.  Clues to immune tolerance: the monogenic autoimmune syndromes.

Authors:  Michael Waterfield; Mark S Anderson
Journal:  Ann N Y Acad Sci       Date:  2010-10-22       Impact factor: 5.691

Review 6.  Monogenic autoimmunity.

Authors:  Mickie H Cheng; Mark S Anderson
Journal:  Annu Rev Immunol       Date:  2012-01-06       Impact factor: 28.527

Review 7.  Update in endocrine autoimmunity.

Authors:  Mark S Anderson
Journal:  J Clin Endocrinol Metab       Date:  2008-10       Impact factor: 5.958

8.  Homozygosity of the polymorphism MICA5.1 identifies extreme risk of progression to overt adrenal insufficiency among 21-hydroxylase antibody-positive patients with type 1 diabetes.

Authors:  Taylor M Triolo; Erin E Baschal; Taylor K Armstrong; Carrie S Toews; Pamela R Fain; Marian J Rewers; Liping Yu; Dongmei Miao; George S Eisenbarth; Peter A Gottlieb; Jennifer M Barker
Journal:  J Clin Endocrinol Metab       Date:  2009-10-09       Impact factor: 5.958

9.  BPIFB1 is a lung-specific autoantigen associated with interstitial lung disease.

Authors:  Anthony K Shum; Mohammad Alimohammadi; Catherine L Tan; Mickie H Cheng; Todd C Metzger; Christopher S Law; Wint Lwin; Jaakko Perheentupa; Helene Bour-Jordan; Jean Claude Carel; Eystein S Husebye; Filippo De Luca; Christer Janson; Ravishankar Sargur; Noémie Dubois; Merja Kajosaari; Paul J Wolters; Harold A Chapman; Olle Kämpe; Mark S Anderson
Journal:  Sci Transl Med       Date:  2013-10-09       Impact factor: 17.956

10.  Murine high specificity/sensitivity competitive europium insulin autoantibody assay.

Authors:  Naru Babaya; Edwin Liu; Dongmei Miao; Marcella Li; Liping Yu; George S Eisenbarth
Journal:  Diabetes Technol Ther       Date:  2009-04       Impact factor: 6.118

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.